Team:St Andrews/Modelling

From 2012.igem.org

(Difference between revisions)
Line 1: Line 1:
 +
{{:Team:St_Andrews/Template:Header}}
{{:Team:St_Andrews/Template:Header}}
Line 25: Line 26:
     <ul class="nav nav-pills">
     <ul class="nav nav-pills">
       <li><a href="#introduction">Introduction</a></li>
       <li><a href="#introduction">Introduction</a></li>
-
       <li><a href="#data-collection">Data Collection</a></li>
+
       <li><a href="#model">Model</a></li>
     </ul>
     </ul>
   </div>
   </div>
Line 39: Line 40:
<h1>Introduction</h1>
<h1>Introduction</h1>
-
<p>While Team St Andrews' \Omega Squad" works to produce EPA Omega 3
+
<p>While Team St Andrews' "Omega Squad" works to produce EPA Omega 3
-
Fatty Acids in the Laboratory; our \Mod Squad" motivates their endeav-
+
Fatty Acids in the Laboratory; our "Mod Squad" motivates their endeav-
ours, quantitatively. In particular, we seek to model the time evolution of
ours, quantitatively. In particular, we seek to model the time evolution of
human-available EPA and DHA Omega 3 Fatty Acids from the year 1950
human-available EPA and DHA Omega 3 Fatty Acids from the year 1950
and into the future. We will also investigate recent trends indicating in-
and into the future. We will also investigate recent trends indicating in-
creasing demand for these resources: due to population growth, as well as
creasing demand for these resources: due to population growth, as well as
-
heightened awareness of the health bene�ts associated with a diet containing
+
heightened awareness of the health benefits associated with a diet containing
these Fatty Acids.</p>
these Fatty Acids.</p>
</section>
</section>
 +
 +
<section id="model">
 +
<br>
 +
<h1>Introduction</h1>
 +
 +
<p></p>
 +
</section>
 +
 +
<!-- Our model
 +
================================================== -->
 +
<section id="model">
 +
<br>
 +
<h1>Introduction</h1>
 +
 +
<p>Our Model relies on a number of assumptions:</p>
 +
  <p><b>Assumption 1:<b> Humans obtain their necessary EPA and DHA Omega 3 Fatty Acids from fish, and fish alone. (Insert justification for this assump- tion)</p>
 +
  <p><b>Assumption 2:</b> In addition to Assumption 1, only mature fish (insert clear definition of “mature”) can be considered a source of EPA and DHA. (Justification: current catch is composed mostly of mature fish (data to sup- port statement). This assumption also greatly simplifies our model: refer to Equation (4) later in this document)</p>
 +
  <p>Let <i>ω(t)</i> represent the DHA and EPA Omega 3 available for human con- sumption at time <i>t</i> years (in tonnes). Further, let <i>B(t)</i> represent total ma- ture fish biomass in the world at time <i>t</i> years (again, in tonnes) and <i>ωB(t)</i> represent the average Omega 3 (DHA + EPA) content per tonne of mature fish biomass at t.</p>
 +
 +
</section>
<!-- Introduction
<!-- Introduction
================================================== -->
================================================== -->
<section id="introduction">
<section id="introduction">
-
<br>
+
  <br>
<h1>Introduction</h1>
<h1>Introduction</h1>
-
<p>While Team St Andrews' \Omega Squad" works to produce EPA Omega 3
+
  <p>While Team St Andrews' \Omega Squad" works to produce EPA Omega 3
Fatty Acids in the Laboratory; our \Mod Squad" motivates their endeav-
Fatty Acids in the Laboratory; our \Mod Squad" motivates their endeav-
ours, quantitatively. In particular, we seek to model the time evolution of
ours, quantitatively. In particular, we seek to model the time evolution of
Line 64: Line 85:
these Fatty Acids.</p>
these Fatty Acids.</p>
</section>
</section>
 +
 +
<!-- Data collection
<!-- Data collection

Revision as of 16:48, 11 July 2012

Resource: Omega 3

Past, Present and Future Supply and Demand


Introduction

While Team St Andrews' "Omega Squad" works to produce EPA Omega 3 Fatty Acids in the Laboratory; our "Mod Squad" motivates their endeav- ours, quantitatively. In particular, we seek to model the time evolution of human-available EPA and DHA Omega 3 Fatty Acids from the year 1950 and into the future. We will also investigate recent trends indicating in- creasing demand for these resources: due to population growth, as well as heightened awareness of the health benefits associated with a diet containing these Fatty Acids.


Introduction


Introduction

Our Model relies on a number of assumptions:

Assumption 1: Humans obtain their necessary EPA and DHA Omega 3 Fatty Acids from fish, and fish alone. (Insert justification for this assump- tion)

Assumption 2: In addition to Assumption 1, only mature fish (insert clear definition of “mature”) can be considered a source of EPA and DHA. (Justification: current catch is composed mostly of mature fish (data to sup- port statement). This assumption also greatly simplifies our model: refer to Equation (4) later in this document)

Let ω(t) represent the DHA and EPA Omega 3 available for human con- sumption at time t years (in tonnes). Further, let B(t) represent total ma- ture fish biomass in the world at time t years (again, in tonnes) and ωB(t) represent the average Omega 3 (DHA + EPA) content per tonne of mature fish biomass at t.


Introduction

While Team St Andrews' \Omega Squad" works to produce EPA Omega 3 Fatty Acids in the Laboratory; our \Mod Squad" motivates their endeav- ours, quantitatively. In particular, we seek to model the time evolution of human-available EPA and DHA Omega 3 Fatty Acids from the year 1950 and into the future. We will also investigate recent trends indicating in- creasing demand for these resources: due to population growth, as well as heightened awareness of the health bene�ts associated with a diet containing these Fatty Acids.


Data collection

When $a \ne 0$, there are two solutions to \(ax^2 + bx + c = 0\) and they are $$x = {-b \pm \sqrt{b^2-4ac} \over 2a}.$$

Back to top

University of St Andrews, 2012.

Contact us: igem2012@st-andrews.ac.uk, Twitter, Facebook

This iGEM team has been funded by the MSD Scottish Life Sciences Fund. The opinions expressed by this iGEM team are those of the team members and do not necessarily represent those of Merck Sharp & Dohme Limited, nor its Affiliates.